You are currently viewing a new version of our website. To view the old version click .

Pharmaceuticals, Volume 17, Issue 3

March 2024 - 138 articles

Cover Story: This review highlights the substantial benefit that peptide receptor radionuclide therapy (PRRT) with an α-emitting radionuclide may offer patients with neuroendocrine tumors (NETs). The radiobiological basis for using α-emitters, based on their high linear energy transfer and short range, was discussed. Candidate α-emitters were critically evaluated. The current published literature for targeted alpha therapy of NETs was reviewed, from in vitro to clinical experience, showing a response rate far exceeding that expected from β-PRRT. Despite promising results, studies are heterogeneous, and treatment is non-optimized. It is hoped that theragnostic imaging and dosimetry will aid in understanding the relationships between activity, absorbed dose, therapeutic response, and toxicity to facilitate this optimization for future patients. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (138)

  • Review
  • Open Access
3 Citations
4,295 Views
48 Pages

21 March 2024

Schizophrenia is a serious mental disorder that significantly affects the social and professional life of patients, causing distortion of reality and loss of identity and cognitive abilities. Psychopharmacological treatment is an integral part of mod...

  • Article
  • Open Access
6 Citations
3,687 Views
19 Pages

Chlojaponilactone B Attenuates THP-1 Macrophage Pyroptosis by Inhibiting the TLR/MyD88/NF-κB Pathway

  • Qiyin Wen,
  • Bingjinfeng Zhan,
  • Lu Jin,
  • Zijing Peng,
  • Ju Liu,
  • Longping Zhu,
  • Depo Yang,
  • Xinjun Xu,
  • Lixia Zhang and
  • Ge Li
  • + 1 author

21 March 2024

Pyroptosis, an innate immune response, plays a crucial role in the pathological process of inflammatory diseases. Although pyroptosis blockade is considered a potential therapeutic strategy, no ideal candidate drug has been identified. The natural pr...

  • Article
  • Open Access
2,264 Views
15 Pages

The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology

  • Erika Ongemach,
  • Daniela Zerrinius,
  • Philipp Heimann,
  • Christian Rainer Wirtz,
  • Klaus-Michael Debatin,
  • Mike-Andrew Westhoff and
  • Aurelia Peraud

21 March 2024

Glioblastoma, the most common and lethal primary adult brain tumor, cannot be successfully removed surgically due to its highly invasive nature. Therapeutically, approaches must be aimed at a systemic brain disease and not merely at a tumor located w...

  • Article
  • Open Access
5 Citations
5,190 Views
21 Pages

21 March 2024

The aim of this study was to determine the drug loading capacity of phosphatidylcholine-based formulations for four poorly water-soluble drug substances (clofazimine, fenofibrate, artemether, cannabidiol). Two self-dispersing lipid formulations were...

  • Review
  • Open Access
4 Citations
2,703 Views
11 Pages

Terpenes from Cecropia Species and Their Pharmacological Potential

  • Preslav Enchev,
  • Yancho Zarev,
  • Anzhelica Dakovska,
  • Andrés Rivera-Mondragón,
  • Ekaterina Kozuharova and
  • Iliana Ionkova

20 March 2024

Cecropia is a genus of neotropical trees mainly distributed in Mexico and Central and South America. Currently, 63 species have been described, some of which have been used for centuries in traditional medicine to treat conditions such as diabetes, h...

  • Review
  • Open Access
9 Citations
5,652 Views
31 Pages

20 March 2024

Lactoferrins and lactoferrin-derived peptides display numerous functions linked to innate immunity in mammalians, spanning from antimicrobial to anti-inflammatory and immunomodulatory actions, and even demonstrate antitumor properties. To date, the p...

  • Article
  • Open Access
2 Citations
2,883 Views
18 Pages

Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with A2AR/A2BR

  • Rosario García-Rocha,
  • Alberto Monroy-García,
  • Ana Luisa Vázquez-Cruz,
  • Luis Antonio Marín-Aquino,
  • Benny Weiss-Steider,
  • Jorge Hernández-Montes,
  • Christian Azucena Don-López,
  • Gabriela Molina-Castillo and
  • María de Lourdes Mora-García

19 March 2024

The present study provides evidence showing that adenosine (Ado) increases the expression of programmed death ligand 1 (PD-L1) in cervical cancer (CeCa) cells by interacting with A2AR/A2BR and that TGF-β1 acts in an autocrine manner to induce PD...

  • Review
  • Open Access
22 Citations
15,643 Views
36 Pages

19 March 2024

Over the last several decades, a growing body of research has investigated the potential to repurpose the anti-diabetic drug metformin for breast cancer prevention and/or treatment. Observational studies in the early 2000s demonstrated that patients...

  • Article
  • Open Access
11 Citations
5,103 Views
17 Pages

Digital Technology Applications in the Management of Adverse Drug Reactions: Bibliometric Analysis

  • Olena Litvinova,
  • Andy Wai Kan Yeung,
  • Fabian Peter Hammerle,
  • Michel-Edwar Mickael,
  • Maima Matin,
  • Maria Kletecka-Pulker,
  • Atanas G. Atanasov and
  • Harald Willschke

19 March 2024

Adverse drug reactions continue to be not only one of the most urgent problems in clinical medicine, but also a social problem. The aim of this study was a bibliometric analysis of the use of digital technologies to prevent adverse drug reactions and...

  • Article
  • Open Access
13 Citations
6,330 Views
13 Pages

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System

  • Rosanna Ruggiero,
  • Nunzia Balzano,
  • Maria Maddalena Nicoletti,
  • Gabriella di Mauro,
  • Federica Fraenza,
  • Maria Rosaria Campitiello,
  • Francesco Rossi and
  • Annalisa Capuano

19 March 2024

The recent introduction of the innovative therapy, onasemnogene abeparvovec (Zolgensma®), has revolutionized the spinal muscular atrophy (SMA) therapeutic landscape. Although Zolgensma® therapy has proven to lead to functional improvements in...

of 14

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceuticals - ISSN 1424-8247